应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
NTRA Natera, Inc.
交易中 01-20 10:16:50 EST
229.29
-1.96
-0.85%
最高
232.40
最低
226.66
成交量
16.17万
今开
228.08
昨收
231.25
日振幅
2.48%
总市值
317.16亿
流通市值
309.54亿
总股本
1.38亿
成交额
3,714万
换手率
0.12%
流通股本
1.35亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
伊克力西斯与Natera就结直肠癌药物Zanzalintinib的关键性III期试验Stellar-316达成合作
美股速递 · 01-07
伊克力西斯与Natera就结直肠癌药物Zanzalintinib的关键性III期试验Stellar-316达成合作
Natera Inc 提交出售多达195万股普通股的申请 - SEC备案
美股速递 · 2025-12-10
Natera Inc 提交出售多达195万股普通股的申请 - SEC备案
Natera Inc:完成2.75亿美元前期全股票交易及额外1.75亿美元的权益补偿协议
美股速递 · 2025-12-05
Natera Inc:完成2.75亿美元前期全股票交易及额外1.75亿美元的权益补偿协议
Natera第三季度收入5.922亿美元,超出IBES预期的5.125亿美元
投资观察 · 2025-11-20
Natera第三季度收入5.922亿美元,超出IBES预期的5.125亿美元
Natera, Inc.: Imvigor011试验取得成功,膀胱癌患者整体生存率提高41%
美股速递 · 2025-10-20
Natera, Inc.: Imvigor011试验取得成功,膀胱癌患者整体生存率提高41%
Natera:额外口头报告包括Sunrise-4试验结果、结直肠癌Intercept试验以及Natera早期癌症检测项目
美股速递 · 2025-10-13
Natera:额外口头报告包括Sunrise-4试验结果、结直肠癌Intercept试验以及Natera早期癌症检测项目
NeoGenomics专利诉讼胜利对股价构成利好 -- 市场观察
投资观察 · 2025-08-30
NeoGenomics专利诉讼胜利对股价构成利好 -- 市场观察
异动解读 | Natera股价盘前大涨13.43%,Q2业绩超预期
异动解读 · 2025-08-08
异动解读 | Natera股价盘前大涨13.43%,Q2业绩超预期
异动解读 | 业绩超预期,Natera夜盘大涨10.83%
异动解读 · 2025-08-08
异动解读 | 业绩超预期,Natera夜盘大涨10.83%
Natera 2025财年Q2业绩会总结及问答精华:创新推动增长
业绩会速递 · 2025-08-08
Natera 2025财年Q2业绩会总结及问答精华:创新推动增长
Piper Sandler:维持Natera(NTRA.US)评级,由增持调整至增持评级, 目标价由200.00美元调整至205.00美元。
金融界 · 2025-03-05
Piper Sandler:维持Natera(NTRA.US)评级,由增持调整至增持评级, 目标价由200.00美元调整至205.00美元。
Baird:维持Natera(NTRA.US)评级,由优于大市调整至优于大市评级, 目标价由183.00美元调整至188.00美元。
金融界 · 2025-02-28
Baird:维持Natera(NTRA.US)评级,由优于大市调整至优于大市评级, 目标价由183.00美元调整至188.00美元。
Natera 2024年第四季度GAAP每股收益 $(0.41) 超预期,销售额 $4.761亿超预期 $4.2855亿
财报速递 · 2025-02-28
Natera 2024年第四季度GAAP每股收益 $(0.41) 超预期,销售额 $4.761亿超预期 $4.2855亿
Natera, Inc.盘中异动 大幅上涨5.06%报176.73美元
市场透视 · 2025-01-30
Natera, Inc.盘中异动 大幅上涨5.06%报176.73美元
高盛:维持Natera(NTRA.US)评级,由买入调整至买入评级, 目标价由160.00美元调整至190.00美元。
金融界 · 2025-01-28
高盛:维持Natera(NTRA.US)评级,由买入调整至买入评级, 目标价由160.00美元调整至190.00美元。
Natera(NTRA.US)获巴克莱首次覆盖,给予增持评级, 目标价200.00美元。
金融界 · 2025-01-24
Natera(NTRA.US)获巴克莱首次覆盖,给予增持评级, 目标价200.00美元。
Natera, Inc.盘中异动 下午盘股价大涨5.02%报166.31美元
市场透视 · 2025-01-22
Natera, Inc.盘中异动 下午盘股价大涨5.02%报166.31美元
特朗普2.0时代即将开启,投资机会如何掘金?
招商基金 · 2025-01-20
特朗普2.0时代即将开启,投资机会如何掘金?
Natera, Inc.盘中异动 早盘股价大跌5.14%报159.84美元
市场透视 · 2025-01-17
Natera, Inc.盘中异动 早盘股价大跌5.14%报159.84美元
Guggenheim:维持Natera(NTRA.US)评级,由买入调整至买入评级, 目标价由170.00美元调整至200.00美元。
金融界 · 2025-01-17
Guggenheim:维持Natera(NTRA.US)评级,由买入调整至买入评级, 目标价由170.00美元调整至200.00美元。
加载更多
公司概况
公司名称:
Natera, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Natera, Inc.于2007年1月在特拉华州成立。该公司是一家诊断公司,拥有专有的分子和生物信息技术,该公司正在应用该技术来改变全球范围内的疾病管理。该公司的无细胞DNA(CFDNA)技术结合了新颖的分子分析方法,这些方法可以从小到单个细胞的样本中可靠地测量整个基因组中的许多信息区域,以及统计算法,这些算法结合了更广泛的科学界提供的数据,以高精度和高覆盖率识别涵盖广泛严重疾病的遗传变异。该公司的目标是使个性化基因检测和诊断成为保护健康的护理标准的一部分,并告知更早和更有针对性的干预措施,以帮助实现更长寿、更健康的生活。
发行价格:
--
{"stockData":{"symbol":"NTRA","market":"US","secType":"STK","nameCN":"Natera, Inc.","latestPrice":229.29,"timestamp":1768922208302,"preClose":231.25,"halted":0,"volume":161666,"delay":0,"changeRate":-0.00847567567567571,"floatShares":135000000,"shares":138321138,"eps":-2.290471,"marketStatus":"交易中","change":-1.96,"latestTime":"01-20 10:16:50 EST","open":228.08,"high":232.4,"low":226.66,"amount":37136355.059760004,"amplitude":0.024822,"askPrice":229.65,"askSize":100,"bidPrice":228.95,"bidSize":30,"shortable":3,"etf":0,"ttmEps":-2.290471,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1768942800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1435809600000,"exchange":"NASDAQ","adjPreClose":231.25,"preHourTrading":{"tag":"盘前","latestPrice":227,"preClose":231.25,"latestTime":"09:12 EST","volume":868,"amount":197053.2298,"timestamp":1768918350635,"change":-4.25,"changeRate":-0.018378,"amplitude":0.017254},"postHourTrading":{"tag":"盘后","latestPrice":231.25,"preClose":231.25,"latestTime":"19:35 EST","volume":41570,"amount":9611818.97,"timestamp":1768610116092,"change":0,"changeRate":0,"amplitude":0.04},"volumeRatio":1.069531,"impliedVol":0.3862,"impliedVolPercentile":0.1713},"requestUrl":"/m/hq/s/NTRA","defaultTab":"news","newsList":[{"id":"1110382268","title":"伊克力西斯与Natera就结直肠癌药物Zanzalintinib的关键性III期试验Stellar-316达成合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1110382268","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110382268?lang=zh_cn&edition=full","pubTime":"2026-01-07 21:03","pubTimestamp":1767791008,"startTime":"0","endTime":"0","summary":"伊克力西斯与Natera公司宣布将开展战略合作,共同推进名为Stellar-316的III期关键性临床试验。该试验旨在评估Zanzalintinib针对结直肠癌患者的疗效与安全性,标志着双方在肿瘤治疗领域的重要布局。此次合作将整合伊克力西斯在靶向药物研发方面的优势与Natera在精准诊断技术领域的专长,为结直肠癌治疗探索新的可能性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0963586101.USD","LU0345770308.USD","LU2065171402.SGD","LU1988902786.USD","LU0012050646.USD","LU0345770993.USD","LU2065731478.USD","LU2065171311.SGD","BK4139","LU1064131342.USD","LU0053671581.USD","EXEL","LU2065170008.USD","LU2065169927.USD","LU0106261612.USD","LU2264538146.SGD","NTRA","BK4532","LU2324357040.USD"],"gpt_icon":0},{"id":"1166069724","title":"Natera Inc 提交出售多达195万股普通股的申请 - SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1166069724","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166069724?lang=zh_cn&edition=full","pubTime":"2025-12-10 22:11","pubTimestamp":1765375870,"startTime":"0","endTime":"0","summary":"Natera Inc 提交出售多达195万股普通股的申请 - SEC备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770993.USD","LU0963586101.USD","NTRA","LU0106261612.USD","LU2065171402.SGD","LU0053671581.USD","LU1064131342.USD","LU2065170008.USD","LU0012050646.USD","BK4139","LU2065169927.USD","LU2264538146.SGD","LU2065731478.USD","LU1988902786.USD","LU2065171311.SGD","LU0345770308.USD","LU2324357040.USD"],"gpt_icon":0},{"id":"1108660167","title":"Natera Inc:完成2.75亿美元前期全股票交易及额外1.75亿美元的权益补偿协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1108660167","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108660167?lang=zh_cn&edition=full","pubTime":"2025-12-05 20:04","pubTimestamp":1764936258,"startTime":"0","endTime":"0","summary":"Natera Inc:完成2.75亿美元前期全股票交易及额外1.75亿美元的权益补偿协议","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1988902786.USD","LU2065171402.SGD","LU0106261612.USD","LU0012050646.USD","LU2065170008.USD","LU0345770308.USD","LU0053671581.USD","LU0963586101.USD","LU2065169927.USD","LU2065171311.SGD","LU2324357040.USD","LU0345770993.USD","BK4139","LU2065731478.USD","NTRA","LU2264538146.SGD","LU1064131342.USD"],"gpt_icon":0},{"id":"1194525752","title":"Natera第三季度收入5.922亿美元,超出IBES预期的5.125亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1194525752","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194525752?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:00","pubTimestamp":1763571644,"startTime":"0","endTime":"0","summary":"11月6日 - Natera第三季度运营收入为-9760万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770993.USD","LU0963586101.USD","NTRA","LU0106261612.USD","LU2065171402.SGD","LU0053671581.USD","LU1064131342.USD","LU2065170008.USD","LU0012050646.USD","BK4139","LU2065169927.USD","LU2264538146.SGD","LU2065731478.USD","LU1988902786.USD","LU2065171311.SGD","LU0345770308.USD","LU2324357040.USD"],"gpt_icon":0},{"id":"1174935558","title":"Natera, Inc.: Imvigor011试验取得成功,膀胱癌患者整体生存率提高41%","url":"https://stock-news.laohu8.com/highlight/detail?id=1174935558","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174935558?lang=zh_cn&edition=full","pubTime":"2025-10-20 13:07","pubTimestamp":1760936830,"startTime":"0","endTime":"0","summary":"Natera, Inc.: Imvigor011试验取得成功,膀胱癌患者整体生存率提高41%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","LU0345770308.USD","LU0963586101.USD","LU2065731478.USD","LU0106261612.USD","LU1064131342.USD","LU2065170008.USD","LU2065171311.SGD","LU2264538146.SGD","LU0345770993.USD","LU0053671581.USD","BK4139","NTRA","LU2065171402.SGD","LU0012050646.USD","LU1988902786.USD","LU2065169927.USD"],"gpt_icon":0},{"id":"1193796018","title":"Natera:额外口头报告包括Sunrise-4试验结果、结直肠癌Intercept试验以及Natera早期癌症检测项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1193796018","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193796018?lang=zh_cn&edition=full","pubTime":"2025-10-13 06:14","pubTimestamp":1760307254,"startTime":"0","endTime":"0","summary":"Natera:额外口头报告包括Sunrise-4试验结果、结直肠癌Intercept试验以及Natera早期癌症检测项目","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2065169927.USD","LU0053671581.USD","LU0963586101.USD","LU2065171311.SGD","LU0345770308.USD","LU2065171402.SGD","LU0345770993.USD","LU1988902786.USD","LU0106261612.USD","NTRA","LU2065170008.USD","LU1064131342.USD","LU2324357040.USD","LU2065731478.USD","LU0012050646.USD","LU2264538146.SGD"],"gpt_icon":0},{"id":"1149199189","title":"NeoGenomics专利诉讼胜利对股价构成利好 -- 市场观察","url":"https://stock-news.laohu8.com/highlight/detail?id=1149199189","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149199189?lang=zh_cn&edition=full","pubTime":"2025-08-30 01:38","pubTimestamp":1756489116,"startTime":"0","endTime":"0","summary":"NeoGenomics在与Natera的专利侵权诉讼中获得简易判决胜利,消除了股票面临的部分诉讼阻力,为股价提供了催化剂,Benchmark分析师Bruce Jackson在研究报告中表示。得益于这一裁决,这家癌症检测公司将能够继续在美国制造、使用、销售和推广其RaDaR ST分子残留疾病检测法。\n另一方面,Natera表示正在评估其选择,包括上诉以及通过其他专利进一步执法。NeoGenomics股价大涨24%,而Natera股价基本持平。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","LU0053671581.USD","LU2065731478.USD","LU2065171402.SGD","NTRA","LU0963586101.USD","LU2264538146.SGD","LU0345770308.USD","LU1988902786.USD","BK4139","LU2065171311.SGD","LU2324357040.USD","LU0345770993.USD","LU0012050646.USD","BK4196","BK4121","LU0106261612.USD","LU2065169927.USD","LU1064131342.USD","NEO"],"gpt_icon":0},{"id":"1186073530","title":"异动解读 | Natera股价盘前大涨13.43%,Q2业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1186073530","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186073530?lang=zh_cn&edition=full","pubTime":"2025-08-08 19:08","pubTimestamp":1754651320,"startTime":"0","endTime":"0","summary":"8月8日周五盘前,生物技术公司Natera, Inc.股价大涨13.43%,主要受益于公司发布的2025财年第二季度强劲财报。根据Natera公布的财报,公司2025财年第二季度实现收入5.466亿美元,同比增长32.2%,远超分析师预期的4.7629亿美元。展望未来,Natera管理层上调了全年收入指引至20.2亿至21亿美元,并将毛利率指引提高至61%-64%。尽管市场渗透率仍然较低,但Natera对其在各类肿瘤检测市场的扩张机会持乐观态度,这也增强了投资者对公司长期增长前景的信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTRA"],"gpt_icon":1},{"id":"1165029792","title":"异动解读 | 业绩超预期,Natera夜盘大涨10.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165029792","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165029792?lang=zh_cn&edition=full","pubTime":"2025-08-08 08:23","pubTimestamp":1754612620,"startTime":"0","endTime":"0","summary":"生物技术公司Natera, Inc.在夜盘交易中股价大涨10.83%,引起投资者广泛关注。根据Natera公布的财报,公司2025财年第二季度实现收入5.47亿美元,同比增长32%,环比增长9%,超出分析师预期。Natera的业绩增长主要得益于其肿瘤检测量创下新高,以及改善的报销动态。尽管市场渗透率仍然较低,但Natera管理层对公司在各类肿瘤检测市场的扩张机会持乐观态度,这也增强了投资者对公司长期增长前景的信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTRA"],"gpt_icon":1},{"id":"1149778830","title":"Natera 2025财年Q2业绩会总结及问答精华:创新推动增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1149778830","media":"业绩会速递","labels":["earningsCall","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149778830?lang=zh_cn&edition=full","pubTime":"2025-08-08 06:52","pubTimestamp":1754607164,"startTime":"0","endTime":"0","summary":"Natera在2025财年第二季度实现了32%的收入增长,达到5.47亿美元,主要得益于肿瘤检测量的创新高和改善的报销动态。同比增长32%,环比增长9%。医生开始在不同肿瘤类型中使用Signatera,显示出广泛的市场机会。Find试验已经开始招募,预计2027年提交FDA。Natera在2025财年第二季度表现强劲,收入和毛利率均超出预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"earningsCall,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"gpt_icon":0},{"id":"2517017626","title":"Piper Sandler:维持Natera(NTRA.US)评级,由增持调整至增持评级, 目标价由200.00美元调整至205.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517017626","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517017626?lang=zh_cn&edition=full","pubTime":"2025-03-05 01:02","pubTimestamp":1741107763,"startTime":"0","endTime":"0","summary":"Piper Sandler:维持Natera(NTRA.US)评级,由增持调整至增持评级, 目标价由200.00美元调整至205.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/05010248524007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NTRA"],"gpt_icon":0},{"id":"2514232708","title":"Baird:维持Natera(NTRA.US)评级,由优于大市调整至优于大市评级, 目标价由183.00美元调整至188.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514232708","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514232708?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:28","pubTimestamp":1740752886,"startTime":"0","endTime":"0","summary":"Baird:维持Natera(NTRA.US)评级,由优于大市调整至优于大市评级, 目标价由183.00美元调整至188.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28222848467014.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NTRA"],"gpt_icon":0},{"id":"1132429857","title":"Natera 2024年第四季度GAAP每股收益 $(0.41) 超预期,销售额 $4.761亿超预期 $4.2855亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1132429857","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132429857?lang=zh_cn&edition=full","pubTime":"2025-02-28 05:10","pubTimestamp":1740690630,"startTime":"0","endTime":"0","summary":"Natera报告季度每股亏损 $,超出分析师普遍预期的 $,超出2.38%。与去年同期销售额 $3.111亿相比,增长了53.04%。以上内容来自Benzinga Earnings专栏,原文如下:Natera reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 2.38 percent. This is a 36.92 percent increase over losses of $ per share from the same period last year. The company reported quarterly sales of $476.10 million which beat the analyst consensus estimate of $428.55 million by 11.10 percent. This is a 53.04 percent increase over sales of $311.10 milli","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Natera 2024年第四季度GAAP每股收益 $(0.41) 超预期,销售额 $4.761亿超预期 $4.2855亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"gpt_icon":0},{"id":"2507425624","title":"Natera, Inc.盘中异动 大幅上涨5.06%报176.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507425624","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507425624?lang=zh_cn&edition=full","pubTime":"2025-01-30 22:54","pubTimestamp":1738248880,"startTime":"0","endTime":"0","summary":"北京时间2025年01月30日22时54分,Natera, Inc.股票出现波动,股价急速拉升5.06%。截至发稿,该股报176.73美元/股,成交量33.0423万股,换手率0.25%,振幅4.15%。Natera, Inc.股票所在的生命科学行业中,整体涨幅为4.20%。Natera, Inc.公司简介:Natera Inc 是一家诊断和研究公司,拥有专有的分子和生物信息学技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130225440abbd50e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130225440abbd50e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2264538146.SGD","LU1064131342.USD","LU0053671581.USD","LU0012050646.USD","BK4139","LU2065171402.SGD","LU2065169927.USD","LU2065171311.SGD","LU1988902786.USD","NTRA","LU2065731478.USD","LU0106261612.USD","LU2065170008.USD"],"gpt_icon":0},{"id":"2507254818","title":"高盛:维持Natera(NTRA.US)评级,由买入调整至买入评级, 目标价由160.00美元调整至190.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507254818","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507254818?lang=zh_cn&edition=full","pubTime":"2025-01-28 23:58","pubTimestamp":1738079888,"startTime":"0","endTime":"0","summary":"高盛:维持Natera(NTRA.US)评级,由买入调整至买入评级, 目标价由160.00美元调整至190.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/28235847883310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NTRA"],"gpt_icon":0},{"id":"2505499060","title":"Natera(NTRA.US)获巴克莱首次覆盖,给予增持评级, 目标价200.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2505499060","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505499060?lang=zh_cn&edition=full","pubTime":"2025-01-24 01:12","pubTimestamp":1737652360,"startTime":"0","endTime":"0","summary":"Natera(NTRA.US)获巴克莱首次覆盖,给予增持评级, 目标价200.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/24011247770023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NTRA"],"gpt_icon":0},{"id":"2505785465","title":"Natera, Inc.盘中异动 下午盘股价大涨5.02%报166.31美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505785465","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505785465?lang=zh_cn&edition=full","pubTime":"2025-01-22 03:29","pubTimestamp":1737487768,"startTime":"0","endTime":"0","summary":"北京时间2025年01月22日03时29分,Natera, Inc.股票出现异动,股价大幅拉升5.02%。截至发稿,该股报166.31美元/股,成交量102.403万股,换手率0.78%,振幅7.00%。Natera, Inc.股票所在的生命科学行业中,整体涨幅为2.44%。Natera, Inc.公司简介:Natera Inc 是一家诊断和研究公司,拥有专有的分子和生物信息学技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122032928a22a946e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122032928a22a946e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2065171402.SGD","LU2065171311.SGD","LU0012050646.USD","LU1988902786.USD","LU0053671581.USD","LU1064131342.USD","LU2065170008.USD","LU2264538146.SGD","LU0106261612.USD","LU2065169927.USD","LU2065731478.USD","BK4139","NTRA"],"gpt_icon":0},{"id":"2504449484","title":"特朗普2.0时代即将开启,投资机会如何掘金?","url":"https://stock-news.laohu8.com/highlight/detail?id=2504449484","media":"招商基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504449484?lang=zh_cn&edition=full","pubTime":"2025-01-20 10:36","pubTimestamp":1737340585,"startTime":"0","endTime":"0","summary":"美国候任总统唐纳德·特朗普将于美东时间1月20日12时正式宣誓就任美国第47任总统。特朗普2.0时代即将开启,有哪些投资机会可以布局?值得一提的是,科技股在特朗普任期内表现尤为突出,成为推动美股上涨的主要力量。在特朗普第一个任期内,美元整体表现相对弱势。4年任期内,美元指数累计下跌了10.53%。而纵观全球市场,在特朗普上一任期内,恒生科技指数涨幅超过147%,表现甚至略微优于纳斯达克指数。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ENTG","EVRG","ODFL","GTLB","LPLA","BPOP","QID","PCAR","SWKS","USJW.SI","AUR","TLN","RYAAY","ALNY","ANSS","HST","FTAI","CDW","RGLD","TTD","LU1815336091.USD","LECO","HOLX","MNST","AFRM","ADBE","RKLB","MPWR","MIDD","REGN","NBIX","FFIV","HSIC","META","AMZN","AMAT","INTU","ONC","AXON","MCHP","LI","AMGN","MEDP","SRPT","RVMD","ORLY","BK4561","OTEX","INSM","MARA","PARA","SBUX","TQQQ","TW","CASY","NVMI","CSWI","TER","MNDY","SEIC","USAW.SI","FCNCA","LU2065731478.USD","BK4550","MKTX","CWST","EWBC","MRNA","OLED","CFLT","NTAP","ULTA","HQY","PFG","EQIX","PTC","CHTR","ROIV","ERIC","NICE","PSQ","ENPH","BRKR","NTES","IDXX","TXN","ZS","MANH","SNPS","BKR","GEN","SMCI","ZM","WTFC","PLTR","MTSI","GEHC","CPRT","PCVX","BMRN","DASH","HOOD","GMAB","JBHT","SSNC","NDAQ","HTHT","SFM","ON","NTNX","BIIB","TSEM","ITCI","ADSK","TEAM","AAL","APA","LNT","EXPE","FTNT","FYBR","CRWD","CTSH","CCEP","BK4588","SBAC","SIRI","NDSN","QXO","STLD","CME","DPZ","FWONK","LAMR","BPMC","JKHY","SOFI","CHDN","TECH","NTRA","DSGX","LSCC","BSY","GILD","MSFT","AAPL","CHRD","NVDA","LOGI","CG","ALGN","COIN","QCOM","FOXA","LU0053671581.USD","GOOGL","MTCH","RADX","CSX","BK4585","DKNG","CSCO","LSTR","WDC","AGNC","NXPI","OKTA","TTEK","CYBR","ROST","BK4593","NWSA","DOCU","PODD","CBSH","INTC","LU0757428866.USD","CSGP","INCY","GNTX","AEP","COO","FAST","FSV","PCTY","ISRG","KDP","PNFP","ROKU","AKAM","FRPT","QQQ","REG","NQmain","LIN","TSCO","DDOG","AMD","COST","BK4534","CHRW","MDLZ","FSLR","QLD","Z","ASML","CDNS","MELI","SQQQ",".IXIC","CINF","EBAY","JD","RIVN","SAIA","ILMN","GRAB","MKSI","TROW","LNW","MRVL","NFLX","LULU","WYNN","DLTR","QRVO","BKNG","TMUS","WWD","ICLR","ARGX","CEG","TCOM","HBAN","TSLA","EXAS","TRMB","EXE","TPG","PEP","ALAB","BK4086","BK4581","ARM","LKQ","DOX","AZN","KHC","ESLT","HLNE","RPRX","DUOL","COKE","MNQmain","FER","PAA","FOX","GLPI","MDB","AVGO","PAYX","TTWO","ROP","MMYT","NVIW.SI","EA","AAON","ADI","HON","CPB","CHKP","POOL","CTAS","ERIE","PDD","STX","WBA","NTRS","TSYW.SI","CZR","RGEN"],"gpt_icon":1},{"id":"2504167168","title":"Natera, Inc.盘中异动 早盘股价大跌5.14%报159.84美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504167168","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504167168?lang=zh_cn&edition=full","pubTime":"2025-01-17 22:57","pubTimestamp":1737125873,"startTime":"0","endTime":"0","summary":"北京时间2025年01月17日22时57分,Natera, Inc.股票出现异动,股价急速下跌5.14%。截至发稿,该股报159.84美元/股,成交量20.4271万股,换手率0.15%,振幅5.54%。Natera, Inc.股票所在的生命科学行业中,整体跌幅为0.14%。Natera, Inc.公司简介:Natera Inc 是一家诊断和研究公司,拥有专有的分子和生物信息学技术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011722575396079ebd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011722575396079ebd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0012050646.USD","LU2065169927.USD","LU2065731478.USD","LU2065171402.SGD","LU0053671581.USD","LU1988902786.USD","BK4139","LU2065171311.SGD","LU0106261612.USD","LU2264538146.SGD","LU2065170008.USD","LU1064131342.USD","NTRA"],"gpt_icon":0},{"id":"2504169979","title":"Guggenheim:维持Natera(NTRA.US)评级,由买入调整至买入评级, 目标价由170.00美元调整至200.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2504169979","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504169979?lang=zh_cn&edition=full","pubTime":"2025-01-17 22:11","pubTimestamp":1737123108,"startTime":"0","endTime":"0","summary":"Guggenheim:维持Natera(NTRA.US)评级,由买入调整至买入评级, 目标价由170.00美元调整至200.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/17221147576704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NTRA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.natera.com","stockEarnings":[{"period":"1week","weight":-0.0131},{"period":"1month","weight":0.0255},{"period":"3month","weight":0.2728},{"period":"6month","weight":0.6649},{"period":"1year","weight":0.3724},{"period":"ytd","weight":0.0094}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Natera, Inc.于2007年1月在特拉华州成立。该公司是一家诊断公司,拥有专有的分子和生物信息技术,该公司正在应用该技术来改变全球范围内的疾病管理。该公司的无细胞DNA(CFDNA)技术结合了新颖的分子分析方法,这些方法可以从小到单个细胞的样本中可靠地测量整个基因组中的许多信息区域,以及统计算法,这些算法结合了更广泛的科学界提供的数据,以高精度和高覆盖率识别涵盖广泛严重疾病的遗传变异。该公司的目标是使个性化基因检测和诊断成为保护健康的护理标准的一部分,并告知更早和更有针对性的干预措施,以帮助实现更长寿、更健康的生活。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":-0.017823},{"month":2,"riseRate":0.6,"avgChangeRate":0.03105},{"month":3,"riseRate":0.5,"avgChangeRate":0.006098},{"month":4,"riseRate":0.7,"avgChangeRate":0.036291},{"month":5,"riseRate":0.8,"avgChangeRate":0.098678},{"month":6,"riseRate":0.8,"avgChangeRate":0.118334},{"month":7,"riseRate":0.4,"avgChangeRate":0.001285},{"month":8,"riseRate":0.818182,"avgChangeRate":0.153134},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.04947},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.038241},{"month":11,"riseRate":0.545455,"avgChangeRate":0.100491},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.000753}],"exchange":"NASDAQ","name":"Natera, Inc.","nameEN":"Natera"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Natera, Inc.(NTRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Natera, Inc.(NTRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Natera, Inc.,NTRA,Natera, Inc.股票,Natera, Inc.股票老虎,Natera, Inc.股票老虎国际,Natera, Inc.行情,Natera, Inc.股票行情,Natera, Inc.股价,Natera, Inc.股市,Natera, Inc.股票价格,Natera, Inc.股票交易,Natera, Inc.股票购买,Natera, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Natera, Inc.(NTRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Natera, Inc.(NTRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}